1 Innovations in Kidney Cancer Guest Expert: Harriet, MD Associate Professor of Medical Oncology Edward, MD Assistant Professor of Surgical Urology
2 Welcome to Yale Cancer Center Answers with Dr. Ed Chu and Dr. Ken. I am Bruce Barber. Dr. Chu is Deputy Director and Chief of Medical Oncology at Yale Cancer Center and Dr. is a medical oncologist specializing in pain and palliative care, and he also serves as the Director of the Connecticut Challenge Survivorship Clinic. If you would like to join the discussion, you can contact the doctors directly. The address is and the phone number is YCC. This evening we look at kidney cancer. Ken welcomes Dr. Harriet and Edward. Dr. is Assistant Professor of Oncology at Yale Cancer Center and Dr. is Chief of the Urology Service and Director of Urologic Oncology at The VA Connecticut Health Care System. Harriet, let's start talking about what causes kidney cancer and why the incidence seems to be increasing. The issue is that, before, patients would come with symptomatic disease and over half of them would come with metastatic disease. Now, with the administration of CAT scan and ultrasound, we are picking up a lot of asymptomatic tumors. If you look at the data, over half of these tumors are presenting asymptomatically so they have come in for some other reason, maybe some GI upset, and a majority of these patients are getting scanned in the emergency room so we are seeing much smaller tumors, but the incidence has jumped significantly in the past few years. Are there patients where the cancer is being diagnosed because of the CAT scan where perhaps it never would have become evident? Absolutely, and I think that the problem is that we are treating it like we used to treat it when they would come in with significant sizes; we would perform surgery for these and have no problem. Now, we are seeing small tumors in the 1-cm range, and beyond even the definition of the CAT scan itself. We know that there is a lesion there, and now we have to follow them with CAT scans. So there is a significant population, especially in our clinics, that we are following and we are not doing anything for them. Is it your sense that the incidence of it is increasing? Is there something in the environment such as cell phones? The incidence of death is also increasing a little so one can assume that perhaps the true incidence is also increasing, not just the incidence of diagnoses. It is not increasing as rapidly and as dramatically as the actual incidence in diagnosis. We were just talking before that in the reports from 2006 they mentioned 35,000 cases in the United States and in 2007 it went up to just over 50,000. For 2008 the projected incidences are 54,000 and that is a dramatic increase in incidence. 2:59 into mp3 file
3 It really is. Whether or not it is true new cases, or just earlier detection and detection of things that in the past would have been missed, we do not really know. But we assume that it is more the detection of things that would have been missed in the past. Is there a difference between kidney cancer and renal cell carcinoma? Kidney cancer essentially means cancer that arises in the kidney. There is a whole batch of different types of cells in the kidney and one of them is a renal cell, or renal tubular cell. Without getting into too many technical details, renal carcinoma is a majority of the kidney cancers, but not all of them. You can have lymphoma of the kidney, you can have renal pelvis cancer, and so. If you look at the literature, everyone uses kidney cancer, and they are basically talking about renal cell carcinoma because that is about 95% of the cancers. Although we are seeing more of these cancers we may not be treating all of them. It is not that they do not need to be treated, but we are seeing them in a lot of different age groups and with some of the age groups their life expectancy is very short and they have significant comorbidities, and subsequently, observation does become a treatment option. For example, if you find a kidney cancer in a person in their late 80s, might you adopt that kind of watchful waiting approach? Absolutely, we bring it up because there is some data, especially from the Toronto Group who has followed a significant portion of patients who have had significant co-morbidities, which make us not want to treat them. When you start to bring in new modalities of treatment, we have a different way of treating patients that is not surgery; they do not go under anesthesia. Some people just do not want anything done first of all, but now we can treat things minimally invasively. I usually give everyone an option for treatment. Who develops kidney cancers more, men or women? Are there certain ages or certain parts of the country that develop it more? More men than women and it is more common in African Americans. It is also more common in people with other risk factors which include smoking, obesity, and certain hereditary conditions. 5:30 into mp3 file
4 I want to get into some of the issues about how you make a diagnosis. If a patient has a CAT scan for some other reason, and you find a small little mass in the kidney, say 1 cm or half an inch, how do you decide if it actually is a cancer and then how do you embark on the treatment plan? Our main issue is this lesion in the kidney; is it solid or not? A lot of patients have cystic lesions which require no follow-up. The way we find out if it is solid and potentially cancerous is we do a CAT scan and we give IV contrast, but these days even people coming to the emergency room are getting contrast, so we can usually tell by the referral with the CAT scan if this is likely to be a malignant. How do you take it from there in terms of biopsies? That is a very, very interesting question because with most cancers the mainstay is a needle biopsy. Kidney cancer is a little different here. There is a sampling error when we do biopsies in which you can get normal tissue and maybe did not actually hit the lesion. You definitely wouldn't want to watch a lesion like that. Basic standard of care is to excise the lesion or to take the whole kidney out, and under pathologic examination of the whole kidney or whole lesion, we decide if it is malignant or not. The majority is malignant, but as we start to find these much smaller tumors like we discussed earlier, the malignancy rate is actually decreasing, but it is still around the 80% range. You began to talk a little bit about minimally invasive ways of treating cancer, which you have said is very exciting compared to taking the entire kidney out, can you tell us more about that? The two main groups are either surgery, or ablation for treatment. Standard surgery can be done where we make an incision or cut the abdomen or side of the body, or we can do it laparoscopically. That is also called minimally invasive therapy. If you want to look at the most minimally invasive therapy, we are talking about ablation therapies. We do not do those through incisions. At the most invasive, we will do it laparoscopically through little holes in the abdomen, or what I specialized in, which is percutaneous treatment. The majority of treatments I do now are percutaneous, where I put the needle straight through the skin. This is a 17-gauge needle which is very, very small and we do that with minimal local sedation. I do it under the CAT scanner and they can go home the same day with just a Band-Aid on the side of the body. You put a needle right into the tumor and then what? 8:31 into mp3 file
5 There are two ways to do it. Once you get the needle in there you could either kill the tumor by heating it, which is called radiofrequency ablation, or you can freeze it, which is called cryotherapy. I do both of them but cryotherapy does have its advantages. You can see the ice ball in the freezing zone much more accurately and so that is my modality of choice. Does that work as well as surgery? That is where things get a little sticky because the technology is going well beyond what our study has shown. With minimally invasive ablative therapies, we only have intermediate data. We are talking about 3 or 4 years of following these patients and seeing what the treatment rates are, but early on, the intermediate data looks very good. If you look at our protocol that we have, we have a 100% treatment rate where we have no enhancement post-treatment, which is what we call 100% cure. Harriet, we talk about local control for the cancer itself, but I know as a medical oncologist your speciality is on the entire body. What are some of the concerns and risks for people that have had a cancer in the kidney? When the patient first comes in we do what we called staging. We try to see the extent of the tumor, if it is localized to the kidney or potentially one lymph node, we will resect it all and sometimes it has gone beyond that. If it is metastasized a little we will still perform surgery. After surgery you have patients who have no evidence of disease by any kind of CAT scan, and then you have patients who have measurable disease and they are treated very differently. For the patients who have no evidence of disease, a certain percentage of them will have a recurrence and that percentage depends on how much disease they had in the first place and how aggressive the disease was. In an individual patient we can never say with 100% certainty whether the tumor is going to come back at any point or not. We have a whole batch of different clinical trials for these patients to see if we can decrease the likelihood of the tumor coming back. The other groups of patients are the patients that have measurable disease, whether they had their kidney taken out or not, and those are treated very differently. If there is residual disease, it is not respectable and we have to then treat them with something that is either in IV or pill form so it can go to all different parts of the body; this is also a very, very exciting arena. We started offering this in the 1990s, with our first drug approved by the FDA for kidney cancers called high-dose interleukin-2. There is about a 20% response rate for kidney cancer and some of those responses end up being cured. Some of the patients that were treated in the 1980s have never had a recurrence. However, from 1995 onwards, we had nothing else to offer the other 80% of patients, and standard, old-fashioned 11:36 into mp3 file
6 chemotherapy does not really work for kidney cancer. But right now, we are on the verge of a revolution in the way we treat kidney cancer. Over the last three years, three drugs have been approved by the FDA for kidney cancer; 3 additional drugs and another one is about to be approved. This has changed the way we approach this disease. People say kidney cancer is different than other types of cancer because it has some unusual qualities. What are they and what makes it unique? It is a very strange tumor that it is not radiosensitive and it is not chemosensitive until these specific inhibitors came out, but what we did see in this tumor group was that some of these patients had regression and their body could fight it and get rid of the tumor, and that is where the big push was for these immunotherapies like interleukin-2. My training was at the National Cancer Institute and a lot of that was with the immunotherapy group. That is why other things such as bone marrow transplants and those sorts of things have always become exciting potential therapies before these types of new drugs that Harriet talked about, these tyrosine kinase inhibitors, were brought to light. In addition, she mentioned that this is a very strange tumor. We actually have a surgical role in metastatic disease. We do take the primary tumor out, and that is not common in most cancers because it has not really been shown to affect the course of the cancer in other diseases, but we have randomized trials that show that it benefits, at least in immunotherapy, so we do take out the primary lesion here. We are going to get back to that in a minute because that is unique and very, very interesting. I would like to remind you that you can your questions to our experts at We are going to take a short break for a medical minute. Please stay tuned to learn more information about kidney cancer with Dr. Harriet and Dr. Edward. Medical Minute Breast cancer is the second most common cancer in women. About 3000 women in Connecticut will be diagnosed with breast cancers this year, but earlier detection, noninvasive treatments, and new therapies are providing more options for breast cancer patients and more women are able to live with breast cancer than ever before. Beginning at age 40, every woman should schedule an annual mammogram and you should start even sooner if you have a risk factor associated with breast cancer. Screening, early detection, and a healthy lifestyle are the most important factors in defeating breast cancer. Clinical trials are currently underway at Federally Designated Comprehensive Cancer Centers such 14:22 into mp3 file
7 as the Yale Cancer Center to make new treatments, not yet approved by the Food and Drug Administration, available to patients. This has been a medical minute, and you will find more information at You are listening to WNPR health forum from Connecticut Public Radio. Welcome back to Yale Cancer Center Answers. This is Dr. Ken and today I am joined by Dr. Harriet and Dr. Edward. We are talking about the treatment options for people with kidney cancer. Edward, if someone has cancer of the kidney that has spread elsewhere, and you take out their kidney, what might happen? It is not just taking it out, they have to get secondary therapy as well. If they re not a candidate for secondary therapy, we do not take the primary lesion out. We do what we call treatment with KIP, which is Kidney in Place. If you have significant metastatic disease, and the primary lesion is not that significant, the oncologist will treat initially with these new inhibitors or immunotherapy. If they respond, we can come back later, but if they are not going to get therapy, we do not take the kidney out because taking out the kidney itself does not do anything; it is only with adjuvant therapy. Something unique about the kidney tumor itself, in addition to the immunotherapy that Edward just mentioned, is that kidney tumors are much more vascular, they contain many, many more blood vessels, so one possibility is that by removing the primary tumor, we are removing the source of all of the growth factors, all of the stimulants for the growth of blood vessels and other places in the body and that might itself help with the therapies that we are subsequently giving. It might also have an immune role as well if we do not remove the primary tumor, because that may be what is inhibiting the immune system to attack the tumors in the other sites in the body. We are not really sure what removing the kidney actually does, but it statistically it appears to help. Most of the new therapies that we have now, that Edward actually mentioned, we call TKIs, or tyrosine kinase inhibitors. It is a very technical term, but essentially these are very small little molecules that hit specific proteins in the tumor, or in the vessels, and stop the growth of the tumor. Some of them are in pill form, some of them are intravenous. Three have been FDA approved in the last couple of years and what we are seeing with kidney patients is that we can never really predict who is going to respond to which one. We are working on trying to do that, but at this point, we do not really know. I think just a few years down the road we are going to be facing a situation that is very similar to what we do in breast cancer. Using that as an example, breast cancer, once it metastasizes, there are many people who have a very good of quality of life for many years. We cannot cure them, but we treat it like a chronic disease 17:36 into mp3 file
8 like with diabetes; we cannot cure them, but people take their insulin and they live their lives. The same with breast cancer where you give one therapy that may last for a few months or for a couple of years, and then it stops working so we move on to the next one. We have a whole menu of therapies that we can choose from and we are heading that way in kidney cancer as well. We think that we are going to soon have a whole menu of drugs. They are not going to help everybody, but they seem to be helping a fair percentage of patients and going forward, we are going to have additional things to choose from, and hopefully, options for patients who do not respond to either immunotherapies or therapies that work on the blood vessel system. This is a very exciting field and as Harriet knows, we study this in the laboratory and in our laboratory specifically, we study the von Hippel- Lindau gene. We are talking about a tumor that has a hereditary group where all of these patients form these tumors. When we look back at those tumors, we find a defect of this von Hippel-Lindau protein. If you look at people who just come off the street that do not have any genetic predisposition to this, the majority also have a defect in this von Hippel- Lindau protein. This von Hippel-Lindau protein is very active in this tumor angiogenesis, this blood vessel issue, and that is why these TK inhibitors that Harriet was talking about are so effective. They are effective with the tumor, but they do not cure, and that is why we concentrate on detecting it early, because with surgery we do cure. I mentioned adjuvant treatment and I probably should not have discussed it in that fashion, because there really is no adjuvant treatment right now. We are doing clinical trials regarding adjuvant treatment after surgery with these high-risk tumors that are very large, anything greater than T1b, that have a high propensity to come back. In these clinical trials we are trying to give these medicines to see if we can decrease that recurrence rate. There is the issue of angiogenesis, or the creation of new blood vessels, and it sounds like you have got some agents that work on that, but you just mentioned this gene for von Hippel-Lindau syndrome. Do you have something that sort of turns off that gene for that group of patients, or is that were the science is headed perhaps? Actually, in the patients that have the mutation, it is off. It is a tumor suppressor gene. But it has some downward pathways that actually turn on because of that, such as hypoxia-inducible factor 1 and 2, so there are a lot of targets for us, especially in our laboratory, looking at inhibiting these pathways for potential treatment modalities in the future. 20:23 into mp3 file
9 Another question for both of you, is there a role for vaccines? Vaccines are being studied heavily for kidney cancer. Vaccines so far have not worked, but on the immunotherapy round that we were talking about earlier, interleukin-2 is a vaccine-like therapy in that it boosts the immune system, but it is not a vaccine in my mind. That is when you give dead cells or weaken cells into a patient and you activate the immune system. We are doing other kinds of immune stimulants. There is another drug called ipilumumab that we have given to melanoma patients fairly extensively and it is being studied as well for kidney cancer. The early studies are showing that there is activity. There are fair numbers of these immune stimulant drugs that are going to be coming down the pipeline and we will be trying them in kidney cancer as well. In terms of your own research, what are some of the things you are working on that you are excited about? We are finding new pathways, not just the von Hippel-Lindau gene, the tumor suppressor gene being faulty, but what it effects in the pathways, what downstream pathways and potential targets, because you look at all these therapies and they do have side effects. We are trying to be very specific in our treatment, not like standard chemotherapy which does affect a lot of different cells that are rapidly dividing. We are actually hitting and inhibiting specific pathways. If you look at most of the research right now that is what we are looking at trying to find. We are also looking for new ways of diagnosing it by looking at tumor tissue arrays and genes and things that are up regulated in this cancer. Immunotherapy still is a hot field. If you look at interleukin-2, although the response rate is not as exciting as the new TK inhibitors you are talking about, these are durable responses. There are 10% that are actually cured and we do not get that with the TK inhibitors. I do not think that it is necessarily a treatment that has gone to the wayside, it has a lot of side effects and things but it is still an option. On the contrary, when we have a young, robust, healthy person who can handle interleukin-2 that is the treatment of choice. Only if it does not work on that patient do we go to the antiandrogenic approach, specifically for the reasons that Edward just mentioned. We can actually cure the small percentage, or we can cure them with the interleukin-2, so we will try that first. That is why I send patients to Harriet at Yale Group, because not everyone is that aggressive, and what we are really shooting for is long-term care here. 23:03 into mp3 file
10 What are some of the clinical trials that are available for people with kidney cancer, at Yale and elsewhere? We have a trial involving two drugs called, 5-Azacytidine and interferon. We are giving it for melanoma and kidney cancer and we have seen a couple of responses with that. We have a number of very novel therapies. They are all additional new, small, molecules that we are trying for patients to see if we can increase that repertoire of approaches. Let me ask you sort of the same thing in terms of surgical approaches, are there any new technologies that you are working on that may make a difference for our patients? If you are talking about surgical and minimally invasive technology, there is new technology such as HIFU, which is a high-intensity focused ultrasound, where instead of putting the needle in, we can, like an ultrasound, put it on the side of the body and focus energy straight at the tumor. There would be no incisions, no piercing of the skin at all. That is not FDA approved in the US, but is in clinical trials, so there are things on the horizon and there are other things that I have been approached with by various biological companies trying to develop even more minimally invasive treatment. There is a lot out there, especially for the surgeon and even the interventionalist who is trying to treat these in a minimally invasive fashion. We have clinical trials looking at adjuvant treatments like we discussed and we work closely with the Natural Cancer Institute. They have a significant amount of trials looking at kidney cancer and also treatment for these hereditary von Hippel- Lindau proteins, and other hereditary cancers such as hereditary papillary renal cell carcinoma. We find that there are a significant amount of genes involved here and they form different types of kidney cancer. This is not uncommon, but it also isn't an incredibly common type of cancer. When a patient is seen at the Yale Cancer Center, what type of multidisciplinary care do they receive and what goes into that? Usually the patient is seen first by the surgeon, though that is not always the case, sometimes they come to us first. We will then image the patient, using a CAT scan or an MRI depending on the patient and the specific situations, and we get pictures. Then we present the patient at our tumor board and at the tumor board we have a pathologist, a radiologist, surgeons and medical oncologists that will present. We discuss how to approach it. Sometimes it is better to give the systemic therapy, in other words the intravenous or pill, first and then try to take out the kidney. Sometimes we do it the other way around and that is the real advantage of having a multidisciplinary clinic. 26:00 into mp3 file
11 The future is multidisciplinary and working together because we definitely want to start to get these trials going. Early on, if I see a metastatic patient, we will call the oncologist and make sure that they are aware and we definitely always have a tumor board and make presentations to make sure that we get different opinions and get a collaborative approach to the treatment of these patients. Unfortunately, it is still a very serious disease, and we do not have a cure for many patients, but is the prognosis improving overall for patients with this diagnosis? Overall it is, but we are also finding them smaller and we find less aggressive tumors, so we do not know if that is a real improvement in the prognosis. It sometimes takes time until you actually see the new drugs starting to help in prolonging life. We have been taking out the kidney or the tumor for a very long time so we know what cure rates are, especially when it is very small and still confined to the kidney. The real key now is to do it with less invasions to the body. We are trying to do this with a focused ultrasound and cryotherapy. Then, at some point, maybe the drug will be so good that we do not have to do any surgery at all. It has been really interesting hearing about the advances, both in terms of surgery and in terms of medical therapy, and the collaboration between what the two of you do; it is great. I want to thank both Dr. Harriet and Dr. Edward for joining us on Yale Cancer Center Answers. Thank you very much. Thank you very much. On behalf of the Yale Cancer Center, I want to wish everyone listening a safe and healthy week. If you have questions, comments, or would like to subscribe to our podcast, go to where you will also find transcripts of past broadcasts in written form. Next week, we will look at the field of psychiatric oncology with Dr. Jimmie Holland. I am Bruce Barber and you are listening to the WNPR health forum from Connecticut Public Radio.
Treatment Advances for Liver Cancer Guest Expert: Wasif, MD Associate Professor of Medical Oncology Mario Strazzabosco, MD Professor of Internal Medicine, Digestive Diseases www.wnpr.org www.yalecancercenter.org
Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome
New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
Understanding Kidney Cancer Guest Expert: Harriet, MD Associate Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Francine Foss,
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
Lung Cancer Awareness Month Update Guest Expert: Frank, MD Professor of Thoracic Surgery Lynn, MD Professor of Pulmonary Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
Clinical Trials for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology Director, Yale Cancer Center Breast Cancer Program www.wnpr.org www.yalecancercenter.org Welcome to Yale
Hosts Anees Chagpar MD Associate Professor of Surgical Oncology Francine MD Professor of Medical Oncology New Methods for Treating Colorectal Cancer Guest Expert: Scott, MD Associate Professor in the Department
Understanding Prostate Cancer Guest Expert: Wm. Kevin, DO Associate Professor of Medical Oncology, Co-director of the Yale Cancer Center Prostate and Urologic Cancers Program www.wnpr.org www.yalecancercenter.org
Leading the Way to Treat Liver Cancer Guest Expert: Sukru, MD Professor of Transplant Surgery Mario Strazzabosco, MD Professor of Internal Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale
The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome
Pfizer Oncology Guest Expert: Louis, MD Director of Clinical Research, Pfizer Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken Miller. I am Bruce
Radiation Oncology Treatment for Gynecological Cancers Guest Expert: Susan, MD Associate Professor of Therapeutic Radiology Yale School of Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale
Innovations in Head and Neck Cancer Guest Expert: Hari Deshpande, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed Chu
The New Frontier (To boldly go... ) Sean A. Pierre, MD, RCPSC (Urology) QUEENSWAY CARLETON HOSPITAL DIVISION OF UROLOGY NEPEAN, ON, CANADA Disclosures None Objectives Advances in the field of Renal Cell
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
RCC RENAL CELL CARCINOMA the most common form of kidney cancer UNDERSTANDINGRCC RENAL CELL CARCINOMA ABOUT THIS GUIDE This guide will: Help you understand renal cell carcinoma (RCC) Provide information
Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer
Useful information for cancer patients Contents This information is an overview of treatments for primary liver cancer. There are sections on Primary or secondary cancer The main treatments for primary
Radiation Therapy for Cancer Treatment Guest Expert: Kenneth, MD Associate Professor of Therapeutic Radiology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and
Cancer Genetic Counseling Guest Expert: Ellen, MS Director of the Yale Cancer Center Cancer Genetic Counseling Program www.wnpr.org www.yalecancercenter.org I am Bruce Barber and this is Yale Cancer Center
A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
Liver Cancer What is the liver? The liver is the largest internal organ in the body and is important in digesting food. The liver performs many other functions, including collecting and filtering blood
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
Patient Resources for Cutaneous T Cell Lymphoma Guest Expert: Jones The Cutaneous Lymphoma Foundation www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed Chu and Dr.
We want to keep prostate cancer from coming back. We re looking for 711 men who want to help. IMPORTANT INFORMATION FOR PROSTATE CANCER PATIENTS The odds are already in your favor. If you have been diagnosed
What is kidney cancer? Renal cell carcinoma (RCC) is the most common kind of kidney cancer. 1 Normally, your kidneys filter your blood and excrete waste in urine. Although our kidneys are important, we
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
Patient Information English Frequently Asked Questions about Kidney Cancer The underlined terms are listed in the glossary. Here is an overview of the most frequently asked questions about kidney cancer.
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular
Researching New Ways to Treat Ovarian Cancer Guest Expert: Gil, MD, PhD Professor of Obstetrics, Gynecology & Reproductive Sciences www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers
A PATIENT S GUIDE TO ABLATION THERAPY THE DIVISION OF VASCULAR/INTERVENTIONAL RADIOLOGY THE ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL Treatment options for patients with cancer continue to expand, providing
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
Liver Cancer And Tumours What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood from all parts of the body, cancer cells from elsewhere can
1 November 28, 2007 State-of-the-art Lung Cancer Treatments Renato Martins, M.D., Hosted by Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
Volume Article.13-11 Publish Date: 24th June 2013 Author(s): MPUH - CRS Team Four Important Facts about Kidney Cancer ARTICLE hhh Muljibhai Patel Urological Hospital (MPUH) Centre For Robotic Surgery (CRS)
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions
Gallbladder cancer Gallbladder cancer is a disease in which malignant (cancer) cells form in the tissues of the gallbladder. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment
EXTRAHEPATIC BILE DUCT CANCER General Information Extrahepatic bile duct cancer is a rare disease in which malignant (cancer) cells form in the part of bile duct that is outside the liver. A network of
Kidney cancer Summary Kidney cancer is more common in people over the age of 55 years. Most kidney cancers are found when the doctor is checking for something else. A person is usually able to live quite
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
Colorectal Cancer Care A Cancer Care Map for Patients Understanding the process of care that a patient goes through in the diagnosis and treatment of colorectal cancer in BC. Colorectal Cancer Care Map
Your Immune System & Melanoma Treatment Immunotherapy and Melanoma Immunotherapy is rapidly emerging as an important approach to treating many forms of cancer. For people with melanoma, the news is particularly
Questions to Ask As You Learn More About Kidney Cancer Now that you have been diagnosed with kidney cancer, it is important for you to understand your condition and your treatment options. Many patients
Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate
Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
A guide for women who are considering breast cancer treatment with chemotherapy and/or hormonal therapy before surgery Contents Introduction... 1 What type of breast cancer do I have?... 2 What treatments
INTRODUCTION APPOINTMENTS P ancreatic cancer is a difficult diagnosis that affects over 45,000 people in the United States each year. Thankfully, improved understanding of risk factors for the disease,
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
Teaming Up Against Sarcoma Recorded on: April 4, 2013 Darin Davidson, MD, MHSc, FRCSC Assistant Professor, Department of Orthopaedics and Sports Medicine University of Washington School of Medicine Robin
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microwave_tumor_ablation 12/2011 11/2015 11/2016 11/2015 Description of Procedure or Service Microwave ablation
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
Hosts Anees MD Associate Professor of Surgical Oncology Francine Foss MD Professor of Hematology Steven Gore MD Director of Hematological Malignancies Melanoma Awareness 2014 Guest Experts: Dale, MD Assistant
Your Immune System & Lung Cancer Treatment Immunotherapy and Lung Cancer Immunotherapy is quickly developing as an important approach to treating many forms of cancer, including lung cancer. Immunotherapy
Treatment Innovations for Esophageal Cancer Guest Experts: Daniel, MD, Assistant Professor, Thoracic Surgery Jill, MD, Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome
Lung Cancer Introduction Lung cancer is the number one cancer killer of men and women. Over 165,000 people die of lung cancer every year in the United States. Most cases of lung cancer are related to cigarette
Underwriting cancer In this issue of the Decision, we provide an overview of Canadian cancer statistics and the information we use to make an underwriting decision. The next few issues will deal with specific
A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T
Story highlights and opportunities: Kidney cancer symptoms can be mistaken for menopause. (Patient example below.) Kidney cancer can be diagnosed incidentally, when being treated for something else. (Patient
Understanding Pancreatic Cancer Understanding Pancreatic Cancer The Pancreas The pancreas is an organ that is about 6 inches long. It s located deep in your belly between your stomach and backbone. Your
Fact Sheet: Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the American Cancer Society, an estimated 1.48 million new
Treating Melanoma Skin Cancer A Quick Guide Contents This is a brief summary of the information on Treating melanoma skin cancer from our website. You will find more detailed information on the website.
General Information About Non-Small Cell Lung Cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing
Pain and Palliative Care for Cancer Patients Guest Expert: Kenneth, MD Assistant Professor of Medical Oncology, Director of Supportive Care, Director of the Connecticut Challenge Survivorship Clinic www.wnpr.org
The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.
Colon cancer Colon cancer is a disease in which malignant (cancer) cells form in the tissues of the colon. The colon is part of the body s digestive system. The digestive system removes and processes nutrients
State-of-the-art Treatment for Prostate Cancer Guest Expert: James, MD Assistant Professor of Therapeutic Radiology at Yale School of Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer
Multiple Myeloma Introduction Multiple myeloma is a type of cancer that affects white blood cells. Each year, thousands of people find out that they have multiple myeloma. This reference summary will help
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
Information for the public Published: 29 July 2015 nice.org.uk About this information NICE guidelines provide advice on the care and support that should be offered to people who use health and care services.
Your consent to our cookies if you continue to use this website.